Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors

References

1. ↵
   Hagspiel KD, Neidl KFW, Eichenberger AC, et al. Detection of liver metastasis: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995;196:471–478

   PubMedWeb of Science
2. Reimer P, Tombach B. Hepatic MR with SPIO: detection and characterization of focal liver lesions. Eur Radiol 1998;8:1198–1204

   CrossRefPubMed
3. Mergo PJ, Engelken JD, Helmberger T, Ros PR. MRI in focal liver disease: a comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents. J Magn Reson Imaging 1998;8:1073–1078

   PubMed
4. ↵
   Saini S, Sharma R, Baron RL, et al. Multicenter dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clin Radiol 2000;55:690–695

   CrossRefPubMedWeb of Science
5. ↵
   Weissleder R, Hahn PF, Stark DD, et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology 1998;169:399–403

   PubMedWeb of Science
6. ↵
   Harisinghani MG, Saini S, Slater GJ, et al. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. J Magn Reson Imaging 1997;7:161–163

   PubMedWeb of Science
7. Nguyen BC, Stanford W, Thompson BH, et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evalution of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging 1999;10:468–473

   CrossRefPubMed
8. ↵
   Hoffman HT, Quets J, Toshiaki T, et al. Functional magnetic resonance imaging using iron oxide particles in characterizing head and neck adenopathy. Laryngoscope 2000;110:1425–1430

   CrossRefPubMed
9. ↵
   Taylor AM, Panting JR, Keegan J, et al. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J Magn Reson Imaging 1999;9:220–227

   CrossRefPubMedWeb of Science
10. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 1997;7:209–214

    CrossRefPubMed
11. ↵
    Bonnemain B. Superparamegetic agents in magnetic resonance imaging: physicochemical characterisitics and clinical applications: a review. J Drug Target 1998;6:167–174

    PubMedWeb of Science
12. ↵
    Xu S, Jordan Ek, Brocke S, et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: early histopathological correlation. J Neurosci Res 1998;52:549–558

    CrossRefPubMedWeb of Science
13. Dousset V, Delalande C, Ballarino L, et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med 1999;41:329–333

    CrossRefPubMedWeb of Science
14. ↵
    Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmmune encephalomyelitis. AJNR Am J Neuroradiol 1999;20:223–227

    Abstract/FREE Full Text
15. ↵
    Neuwelt EA, Weissleder R, Nilaver G, et al. Delivery of virus-sized iron-oxide particles to rodent CNS neurons. Neurosurgery 1994;34:777–784

    PubMedWeb of Science
16. ↵
    Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. AJNR Am J Neuroradiol 1999;20:217–222

    Abstract/FREE Full Text
17. ↵
    Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228–232

    CrossRefPubMedWeb of Science
18. Egelhof T, Delbeck N, Hartmann M, et al. Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas? Radiologe 1998;38:943–947

    PubMed
19. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC Jr, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995;197:533–538

    PubMed
20. ↵
    Moore A, Marecos E, Bogdanov A Jr, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000;214:568–574

    CrossRefPubMedWeb of Science
21. ↵
    Weissleder R, Cheng HC, Bogdanova A, Bogdanov A Jr. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging 1997;7:258–263

    PubMedWeb of Science
22. ↵
    Kroll RA, Pagel MA, Muldoon LL, Neuwelt EA. Increasing volume of distribution to brain with interstitial infusion: dose, rather than convection, may be the most important factor. Neurosurgery 1996;38:746–754

    CrossRefPubMedWeb of Science
23. ↵
    Remsen LG, McCormick CI, Roman-Goldstein S, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol 1996;17:411–418

    Abstract
24. ↵
    Jung C, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661–674

    CrossRefPubMedWeb of Science
25. ↵
    Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083–1100

    CrossRefPubMedWeb of Science
26. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary CNS lymphoma (human non-AIDS) and survival. Neurosurgery 2001;48:1033–1041

    CrossRefPubMedWeb of Science
27. ↵
    Barnett PA, Roman-Goldstein S, Ramsey F, et al. Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat. Am J Path 1995;146:436–449

    PubMedWeb of Science
28. ↵
    Remsen LG, McCormick CI, Sexton G, et al. Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. Neurosurgery 1997;40:1034–1042

    CrossRefPubMed
29. ↵
    Harms SE, Hinton T, Manning L, Korourian S. New MRI contrast agent for labeling of tumor-associated macrophages that stimulate tumor angiogenesis (abstr). In: Proceedings of the Eighth Meeting of the International Society for Magnetic Resonance in Medicine 2000. Berkeley, Calif: International Society for Magnetic Resonance in Medicine,2000;616
30. ↵
    Knauth M, Egelhof T, Roth SU, Wirtz CR, Sartor K. Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. AJNR Am J Neuroradiol 2001;22:99–102

    Abstract/FREE Full Text
31. ↵
    Muldoon LL, Nilaver G, Kroll RA, et al. Comparison of intracerbral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus and iron oxide particles to normal rat brain. Am J Pathol 1995;147:1840–1851

    PubMedWeb of Science